Vaccine. 2021 Dec 16; doi: 10.1016/j.vaccine.2021.12.021. Epub 2021 Dec 16.
Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation.
Vaccine
Samantha J Carlson, Lara McKenzie, Leah Roberts, Christopher C Blyth, Katie Attwell
Affiliations
Affiliations
- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia; VaxPolLab, School of Social Sciences, University of Western Australia, Perth, Western Australia, Australia. Electronic address: [email protected].
- VaxPolLab, School of Social Sciences, University of Western Australia, Perth, Western Australia, Australia.
- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia; VaxPolLab, School of Social Sciences, University of Western Australia, Perth, Western Australia, Australia; School of Medicine, The University of Western Australia, Perth, Western Australia, Australia; Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine WA, Perth, Western Australia, Australia.
- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia; VaxPolLab, School of Social Sciences, University of Western Australia, Perth, Western Australia, Australia.
PMID: 34952758
PMCID: PMC8674511 DOI: 10.1016/j.vaccine.2021.12.021
Abstract
BACKGROUND: On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the "preferred" vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.
METHOD: We undertook qualitative interviews from February - April 2021 before and after the program change with 28 adults in Perth, Western Australia. Using our COVID-19 vaccine intentions model, we assessed changes in participants' COVID-19 vaccine intention before and after the program change. Participants were classified as 1) 'acceptors': no concerns about COVID-19 vaccine safety, efficacy, access and would accept whatever vaccine is offered, 2) 'cautious acceptors': some concerns and would prefer a particular vaccine brand but would accept whatever is offered, 3) 'Wait awhile': for more data, easier access, for another vaccine brand, a greater perceived COVID-19 threat or until mandatory, or 4) 'refuser': no intention to vaccinate due to concerns about safety and/or efficacy.
RESULTS: Before the change, 7/18 of those aged < 50 years were 'acceptors,' 10/18 were 'cautious acceptors' and 1/18 was 'wait awhile.' Overall, 14/18 participants had the same COVID-19 vaccine intention after the change; 4/18 became more concerned. For those aged ≥ 50 years and before the change, 5/10 were 'acceptors' and 5/10 were 'cautious acceptors.' After the change, 8/10 still had the same COVID-19 vaccine intention; 2/10 became more cautious. The major concern before the program change was COVID-19 vaccines having different vaccine efficacy; the concern pivoted to safety.
CONCLUSION: The majority of participants were 'cautious acceptors' who intended on being vaccinated; many had this intention before and after the program change. The Australian government, health care providers and media need to better address COVID-19 vaccine concerns to assist those with COVID-19 vaccine intentions receive a vaccine.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Keywords: Adult; Australia; Covid-19 vaccines; Health Knowledge, Attitudes, Practice; Health policy; Intention; Vaccination
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [SJC, LM, and LR have no confli
References
- J Biomed Inform. 2009 Apr;42(2):377-81 - PubMed
- BMC Public Health. 2017 Jan 23;17(1):106 - PubMed
- BMC Med Res Methodol. 2013 Sep 18;13:117 - PubMed
- Med J Aust. 2021 Jul;215(2):64-67.e1 - PubMed
- Med J Aust. 2021 Jul;215(1):9-12.e1 - PubMed
- BMJ Open. 2021 Jun 30;11(6):e049356 - PubMed
- BMC Infect Dis. 2021 Jan 28;21(1):120 - PubMed
- J Biomed Inform. 2019 Jul;95:103208 - PubMed
- BMC Pediatr. 2012 Sep 21;12:154 - PubMed
- Int J Environ Res Public Health. 2021 Jan 19;18(2): - PubMed
- Vaccine. 2014 Jul 7;32(32):4075-81 - PubMed
- Lancet Infect Dis. 2021 Mar;21(3):318-319 - PubMed
- Vaccine. 2018 Oct 22;36(44):6556-6558 - PubMed
Publication Types